UIC201602

UIC201602 is an investigational small molecule drug developed by Korea United Pharm. It has been studied primarily for its potential use in the treatment of hyperlipemia (hyperlipidemia). The precise mechanism of action for UIC201602 remains unknown, and it does not represent a novel mechanistic class. Clinical development has included Phase 1 studies in healthy volunteers, as well as drug-drug interaction studies with other investigational agents such as UIC201601 and UIC201806. As of now, there are no known adverse events reported, and the drug has not received any regulatory approvals or special designations[1][2][3][10].